Joshua Feder, MD. Dr. Feder has no financial relationships with companies related to this material.
Irritability in pediatric ADHD often persists despite stimulant treatment, yet targeted options are limited. Could an NMDA antagonist already sitting on pharmacy shelves offer a safer adjunct? A small pilot trial reports a striking early signal.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
